Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease
Completed · Phase 1 · NCT05610189
Conditions: Parkinson Disease
At a glance
- Research payments reported, 2025
- $14,700
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 25
About the trial
- Sponsor
- Cerevel Therapeutics, LLC
- Tested
- Tavapadon (drug)
- Dates
- Started 2022-12-15; completion 2023-12-17
- Results posted
- Not yet
The primary purpose of the study is to evaluate the bioequivalence (BE) of tavapadon 15 milligram (mg) tablet to 3x5 mg tablets in participants with Parkinson's disease.
From ClinicalTrials.gov, last updated 2024-02-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $14,700 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Research Centers of America Ll $14,700
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.